Synthetic progestin treatment alters cytokine expression and impairs vaccine response in horses.

Research Overview

• This study investigated how the synthetic progestin altrenogest affects immune function in horses, specifically looking at cytokine levels and the antibody response following vaccination.
• Researchers found that altrenogest treatment suppressed certain immune signaling molecules and weakened the vaccine-induced antibody response in mares.

Background and Purpose

• Altrenogest is a synthetic progestin commonly used in horses for managing reproduction (estrus control, pregnancy maintenance) and behavior.
• Previous research indicated that altrenogest influences immune system components, especially cytokines—small proteins that regulate immune responses.
• The study hypothesized that by altering cytokine production, altrenogest might modify how horses respond to vaccination, potentially reducing vaccine effectiveness.

Study Design and Methods

• Sixteen mares were divided into two groups:
  • 10 mares received injectable altrenogest (100 mg/mL, intramuscular) every 10 days.
  • 6 mares received a placebo injection (1 mL lactated Ringer’s solution, intramuscular) at the same intervals.
• After 30 days of treatment, all mares were vaccinated against equine arteritis virus (EAV) using a commercial vaccine.
• Blood samples were collected before vaccination and at intervals during the 28 days following vaccination.
• Researchers measured:
  • Cytokine levels in serum (including IL-1β, IL-6, IL-10, and IFNγ).
  • Serum neutralizing (SN) antibody titers against EAV to assess vaccine response.
• Data were analyzed using a statistical model for repeated measures to assess the impact of treatment over time, with significance set at P ≤ 0.05.

Key Findings

• Mares treated with altrenogest showed significantly lower serum neutralizing antibody levels at 14 and 21 days after vaccination compared to placebo-treated mares (p < 0.01).
• Altrenogest treatment significantly suppressed the concentrations of key cytokines (IL-1β, IL-6, IL-10, IFNγ) throughout the study period (p < 0.01).

Interpretation and Implications

• The decrease in cytokine levels suggests that altrenogest may suppress immune signaling pathways that are important for generating an effective antibody response.
• The impaired antibody response to EAV vaccine after altrenogest treatment indicates that the drug could reduce vaccine efficacy in mares.
• Since cytokines like IL-1β, IL-6, IL-10, and IFNγ play important roles in activating and regulating immune responses, their suppression likely contributes to the diminished antibody production observed.
• This immune alteration has potential clinical importance because it might decrease the protective effect of vaccinations administered during altrenogest treatment.
• The study recommends further research to evaluate the broader clinical consequences of this immune modulation, including impacts on disease susceptibility and reproductive health.